NFKB1 and neoplasm: The preclinical investigation has shown that metformin can alter macrophage polarisation from an M2 to M1-like phenotype inhibiting tumour growth and angiogenesis and that this may be driven by activation of AMPK/ NF-κB signalling [48, 49].